TengLi Zhang , XunQin Gao , MengTing Liu , Chun Wen , Peng Jin , Hong Yao , XiWang Liu , YingLan Yu , Hao Shao , Lei Luo
{"title":"盐酸氨溴索与四环素类抗生素协同作用于多药耐药肺炎克雷伯菌成熟的生物膜","authors":"TengLi Zhang , XunQin Gao , MengTing Liu , Chun Wen , Peng Jin , Hong Yao , XiWang Liu , YingLan Yu , Hao Shao , Lei Luo","doi":"10.1016/j.bioflm.2025.100315","DOIUrl":null,"url":null,"abstract":"<div><div>Multidrug-resistant <em>Klebsiella pneumoniae</em> (MDR-KP) is a major pathogen responsible for hospital-acquired infections, associated with high morbidity and mortality. Biofilm formation plays a key role in the pathogenicity of MDR-KP and contributes significantly to its antibiotic resistance, substantially impairing the effectiveness of antimicrobial therapies. To enhance the efficacy of existing antibiotics, this study investigates a biofilm-targeting synergistic strategy inspired by the structural similarity between sputum and biofilm matrices. In this study, 87 clinical isolates of MDR-KP were initially screened for biofilm-forming capacity, and strong biofilm producers were selected to establish an <em>in vitro</em> model for systematic evaluation of the anti-biofilm efficacy of six mucolytic agents. Ambroxol hydrochloride (ABH) emerges as the optimal effective, disrupting biofilm structure at 0.7 mg/mL and achieving 50 % clearance within 8 h. ABH enhanced the anti-biofilm activity of tetracycline and doxycycline <em>in vitro</em>, reducing their IC<sub>50</sub> values by 98.9 % and 98.6 %, respectively, against preformed biofilms of MDR-KP compared to monotherapy. Additionally, the excellent physical and chemical compatibility between ABH and tetracycline or doxycycline provides a stable basis for <em>in vivo</em> co-administration. <em>In vivo</em>, the combination alleviates pulmonary inflammation, reduces bacterial load and inflammatory factor levels, and shows no tissue toxicity. In conclusion, ABH combined with tetracycline antimicrobials enhanced their efficacy against MDR-KP infections, especially biofilm-associated infections, in both <em>in vitro</em> and <em>in vivo</em> models, and possessed a favorable physicochemical compatibility and safety profile. These findings suggested that ABH-tetracycline therapy could represent a translationally promising and effective strategy for combating clinical MDR-KP infections.</div></div>","PeriodicalId":55844,"journal":{"name":"Biofilm","volume":"10 ","pages":"Article 100315"},"PeriodicalIF":4.9000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ambroxol hydrochloride as an antibiofilm agent synergizes with tetracycline antibiotics against mature biofilms of multidrug-resistant Klebsiella pneumoniae\",\"authors\":\"TengLi Zhang , XunQin Gao , MengTing Liu , Chun Wen , Peng Jin , Hong Yao , XiWang Liu , YingLan Yu , Hao Shao , Lei Luo\",\"doi\":\"10.1016/j.bioflm.2025.100315\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Multidrug-resistant <em>Klebsiella pneumoniae</em> (MDR-KP) is a major pathogen responsible for hospital-acquired infections, associated with high morbidity and mortality. Biofilm formation plays a key role in the pathogenicity of MDR-KP and contributes significantly to its antibiotic resistance, substantially impairing the effectiveness of antimicrobial therapies. To enhance the efficacy of existing antibiotics, this study investigates a biofilm-targeting synergistic strategy inspired by the structural similarity between sputum and biofilm matrices. In this study, 87 clinical isolates of MDR-KP were initially screened for biofilm-forming capacity, and strong biofilm producers were selected to establish an <em>in vitro</em> model for systematic evaluation of the anti-biofilm efficacy of six mucolytic agents. Ambroxol hydrochloride (ABH) emerges as the optimal effective, disrupting biofilm structure at 0.7 mg/mL and achieving 50 % clearance within 8 h. ABH enhanced the anti-biofilm activity of tetracycline and doxycycline <em>in vitro</em>, reducing their IC<sub>50</sub> values by 98.9 % and 98.6 %, respectively, against preformed biofilms of MDR-KP compared to monotherapy. Additionally, the excellent physical and chemical compatibility between ABH and tetracycline or doxycycline provides a stable basis for <em>in vivo</em> co-administration. <em>In vivo</em>, the combination alleviates pulmonary inflammation, reduces bacterial load and inflammatory factor levels, and shows no tissue toxicity. In conclusion, ABH combined with tetracycline antimicrobials enhanced their efficacy against MDR-KP infections, especially biofilm-associated infections, in both <em>in vitro</em> and <em>in vivo</em> models, and possessed a favorable physicochemical compatibility and safety profile. These findings suggested that ABH-tetracycline therapy could represent a translationally promising and effective strategy for combating clinical MDR-KP infections.</div></div>\",\"PeriodicalId\":55844,\"journal\":{\"name\":\"Biofilm\",\"volume\":\"10 \",\"pages\":\"Article 100315\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2025-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biofilm\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590207525000632\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biofilm","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590207525000632","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
Ambroxol hydrochloride as an antibiofilm agent synergizes with tetracycline antibiotics against mature biofilms of multidrug-resistant Klebsiella pneumoniae
Multidrug-resistant Klebsiella pneumoniae (MDR-KP) is a major pathogen responsible for hospital-acquired infections, associated with high morbidity and mortality. Biofilm formation plays a key role in the pathogenicity of MDR-KP and contributes significantly to its antibiotic resistance, substantially impairing the effectiveness of antimicrobial therapies. To enhance the efficacy of existing antibiotics, this study investigates a biofilm-targeting synergistic strategy inspired by the structural similarity between sputum and biofilm matrices. In this study, 87 clinical isolates of MDR-KP were initially screened for biofilm-forming capacity, and strong biofilm producers were selected to establish an in vitro model for systematic evaluation of the anti-biofilm efficacy of six mucolytic agents. Ambroxol hydrochloride (ABH) emerges as the optimal effective, disrupting biofilm structure at 0.7 mg/mL and achieving 50 % clearance within 8 h. ABH enhanced the anti-biofilm activity of tetracycline and doxycycline in vitro, reducing their IC50 values by 98.9 % and 98.6 %, respectively, against preformed biofilms of MDR-KP compared to monotherapy. Additionally, the excellent physical and chemical compatibility between ABH and tetracycline or doxycycline provides a stable basis for in vivo co-administration. In vivo, the combination alleviates pulmonary inflammation, reduces bacterial load and inflammatory factor levels, and shows no tissue toxicity. In conclusion, ABH combined with tetracycline antimicrobials enhanced their efficacy against MDR-KP infections, especially biofilm-associated infections, in both in vitro and in vivo models, and possessed a favorable physicochemical compatibility and safety profile. These findings suggested that ABH-tetracycline therapy could represent a translationally promising and effective strategy for combating clinical MDR-KP infections.